Lactoferrin in Chronic Pancreatitis

Chun Xiang Jin¹, Tetsuo Hayakawa², Motoji Kitagawa³, Hiroshi Ishiguro⁴

¹Second Clinical College of Norman Bethune Medical Division, Jilin University. Changchun, China. ²Meijo Hospital, Nagoya, Japan. ³Department of Nutritional Science, Nagoya University of Arts and Science. Nisshin, Japan. ⁴Department of Human Nutrition, Nagoya University Graduate School of Medicine, Nagoya Japan

Summary
The present review is focused on the clinical significance of lactoferrin in pancreatic secretions and stone formation in chronic pancreatitis, and of serum anti-lactoferrin antibody in autoimmune pancreatitis. Lactoferrin secretion is increased in pancreatic secretions in calcified and non-calcified chronic pancreatitis. Lactoferrin, pancreatic stone protein and trypsin are present in pancreatic stones. We cannot conclude which protein is more important for the precipitate and stone formation. The presence of anti-lactoferrin antibody has been reported in serum in autoimmune diseases, such as autoimmune pancreatitis. The coincidental appearance of autoimmune pancreatitis with extrapancreatic autoimmune diseases strongly suggests a common autoimmune mechanism and lactoferrin is a candidate antigen. Lactoferrin may play an important role as a precipitate protein in pancreatic stone formation in chronic pancreatitis and as an autoantigen in autoimmune pancreatitis. Further studies are required to better understand the role of lactoferrin.

Introduction
Lactoferrin is an iron-binding protein present mainly in external secretions such as breast milk and polymorphonuclear white cells [1, 2, 3, 4]. The protein is synthesized during the transition of neutrophils from promyelocytes to myelocytes and is stored in the secondary granules [5]. Lactoferrin is released from polymorphonuclear leucocytes on activation of these cells, and its presence in body fluids is proportional to the flux of neutrophils [4, 5, 6, 7]. Determination of the lactoferrin content in various body fluids can be a marker inflammation.

Lactoferrin is normally present in low concentration in pancreatic secretions and the concentration tends to increase in chronic pancreatitis [8]. Therefore, lactoferrin was also incriminated in the past in formation of protein plugs in the pancreatic duct by aggregating with acid macromolecules under decreased secretion of bicarbonate in the pancreatic juice [9, 10]. Chronic pancreatitis is characterized by progressive and irreversible pancreatic damage, parenchymal loss and interstitial fibrosis which eventually result in significant impairment of the exocrine and endocrine pancreatic functions. Additional histopathological features have been described as pancreatic calcification in advanced forms of chronic pancreatitis (regardless of etiology) and a prominent lymphoplasmacytic infiltrate in autoimmune pancreatitis. Additional details of its pathogenesis and mechanism are required regarding its formation in the pancreatic ducts and prominent lymphoplasmacytic infiltrate.

The etiology and prevalence of chronic pancreatitis have been widely reported in India and Asian-Pacific areas as well as in Western countries in the last ten years [11, 12, 13]. The present review will focus on the clinical significance of lactoferrin in pancreatic secretions and stone formation in chronic pancreatitis, and of serum anti-lactoferrin antibody in autoimmune pancreatitis.

Lactoferrin in Pancreatic Juice
An analysis of the protein components of the pancreatic juice is important for clarifying the mechanism of stone formation in the pancreatic duct. Plugs formed by the precipitation of the protein within the interlobular and intralobular ducts are one of the earliest findings in chronic pancreatitis and the protein plugs subsequently perpetuate inflammation of the gland through recurrent obstruction of the pancreatic duct system. If concentration-dependent precipitation is a cause of protein plug formation, some proteins must be
increased, at least, in their concentration. Through analysis of the pancreatic juice, the iron-binding protein, lactoferrin, has been found to be secreted in greater amounts in patients with chronic pancreatitis [8, 14, 15, 16, 17, 18]. Lactoferrin may play a role in the formation of the protein plugs frequently seen in chronic pancreatitis because of their ability to produce the aggregation of a large acidophilic protein, such as albumin [19].

Lactoferrin hypersecretion by the pancreas was initially postulated by Figarella and Sarles to be a congenital secretory defect, possibly worsening the damaging effects of alcohol and malnutrition in the pancreas [10]. Subsequent studies failed to reveal a significant correlation between chronic alcohol consumption and lactoferrin concentration in pancreatic secretion, although they confirmed a hyperconcentration of lactoferrin in both non-calcified and calcified chronic pancreatitis [15]. Lactoferrin hyperconcentration has also been reported in pancreatic juice by Fedail et al. and by Tymppner et al. and in duodenal juice by Brugge and Burke [14, 16, 20]. In our previous reports, we demonstrated the increased secretion of lactoferrin in non-calcified and calcified chronic pancreatitis in both pancreatic and duodenal juice [17, 18, 21]. However, the simultaneous elevation of the protein and lactoferrin in pancreatic secretions occurred in European patients with chronic pancreatitis, but not in Japanese patients [14, 16, 17, 18]. The reasons for the discrepancy are not clear. Brugge and Burke revealed that lactoferrin concentration and its output in duodenal juice, not pure pancreatic juice, were both increased in asymptomatic alcoholics, alcoholics recovered from acute pancreatitis and alcoholics with chronic pancreatitis when compared with those in nonalcoholic healthy subjects [20]. Polymorphonuclear leucocytes were commonly encountered in the pancreatic juice of alcoholics even in those without clinical pancreatitis [19]. Therefore, the presence of leucocytes could account for a part of the increased lactoferrin seen in alcoholics and patients with pancreatic disease since one million polymorphonuclear leucocytes contain 3 µg of lactoferrin.

No increase could be found in lactoferrin concentration in either the plasma or parotid saliva of the controls and patients with chronic pancreatitis [10, 22]. However, increased levels were observed in the parotid saliva of patients with parotid gland disease. Benini et al. have speculated that increased lactoferrin levels in saliva are secondary to the inflammation [22], and it seems probable that the same is also true of the pancreas.

**Lactoferrin in Pancreatic Stones**

Protein analysis of the intraductal precipitates and calculi is important in order to elucidate the mechanism of stone formation in the pancreatic duct. Mariani et al. compared calcified stones obtained from 20 alcoholic patients with radiolucent stones obtained from five non-alcoholic patients [23]. They speculated that the formation of these two types of pancreatic stones was mediated by two different mechanisms. The formation of the calcified radiopaque stones was attributed to the precipitation of calcium carbonate occurring as a consequence of the reduced secretion of pancreatic stone protein which normally functions as an inhibitor of calcium carbonate precipitation. Therefore, pancreatic stone protein reduction could be expected to result in the precipitation of calcium carbonate, leading to stone formation in the pancreatic duct. However, reduction of pancreatic stone protein secretion or an inhibitory effect of calcium precipitation specific to pancreatic stone protein has not yet been confirmed in cases of chronic pancreatitis. Mariani et al. postulated that the formation of radiolucent stones, on the other hand, could be attributed to precipitation of degraded forms of pancreatic stone protein [23]. Thus, stone formation in chronic pancreatitis could be due to the precipitation of either calcium or proteinaceous materials.

Lactoferrin and pancreatic stone protein are thought to be closely related to pancreatic stone formation in chronic pancreatitis. No significant reduction of pancreatic stone protein was observed in either calcified or non-calcified chronic pancreatitis patients [18].

Allan and White proposed a mechanism of protein plug formation, involving the partial activation of pancreatic secretion resulting in precipitation formation in the ductules as an initial step, followed by the development of protein plugs from these precipitations through the slow adsorption of salts and protein from newly-secreted pancreatic juice [9]. Intraductal activation by pancreatic zymogens with the occasional appearance of precipitates in the ductules has been noted in some patients with pancreatitis [9, 24, 25]. Hayakawa et al. observed human cationic trypsin immunoreactivity in protein extracts of pancreatic stones in 11 of 13 patients with chronic calcified pancreatitis, ranging from 0 to 42.3 ng/µg protein [26]. On immunostaining of pancreatic stones, immunoreactivity was observed to be more intense in the amorphous portion of the center of the stones than in the concentric laminar layer of the periphery. Only negligible activity was detected for elastase 1 or amylase in the stone extracts [26]. These results suggest that the presence of trypsinogen in pancreatic stones is not due to coprecipitation or adsorption of pancreatic enzymes but that trypsinogen is more likely involved in an initial step of intraductal precipitate formation than in a subsequent step of stone formation. Jin et al. [27] determined pancreatic stone protein and lactoferrin in pancreatic stones obtained from the 13 patients with chronic calcified pancreatitis same as in the previous study [26]. Pancreatic stone protein was measured in pancreatic stones in all 13 patients, but did not differ significantly between alcoholic (n=6) and non-alcoholic (n=7) pancreatitis. Lactoferrin was detectable in 5 of the 13 patients. There was neither a definite common etiology nor clinical features to explain the high lactoferrin contents.
Autoimmune pancreatitis is a relatively uncommon, non-alcoholic-related form of chronic pancreatitis which has received increasing attention in recent years. Autoimmune pancreatitis is characterized by: i) the presence of increased serum gammaglobulin levels (particularly IgG4); ii) the presence of autoantibodies (anti-lactoferrin autoantibody, antiacinar anhydrase antibodies, rheumatoid factor, and antinuclear antibodies); iii) pancreatic fibrosis with lymphocytic infiltration and absence of pancreatic calcification; iv) association with other autoimmune diseases and v) response to steroid therapy [31]. Chari recently gave the following definition: “autoimmune pancreatitis is a systemic fibroinflammatory disease which affects not only the pancreas but also a variety of other organs including the bile duct, salivary glands, retroperitoneum and lymph nodes. Organs affected by autoimmune pancreatitis have a lymphoplasmacytic infiltrate rich in IgG4 positive cells and the inflammatory process responds to steroid therapy” [32]. The pathogenesis of this disease remains largely unknown but, from clinical and experimental studies, it has been postulated that aberrant HLA-DR expression (in autoimmune pancreatitis HLA-DR expression has been found in pancreatic ductal and acinar cells) leads to the presentation of autoantigens to lymphocytes, resulting in autoimmune response [31]. The presence of serum anti-lactoferrin autoantibody has been reported in patients with autoimmune-related disease, such as autoimmune pancreatitis [33, 34, 35, 36, 37, 38, 39, 40, 41], autoimmune hepatitis [42, 43, 44], systemic lupus erythematosus [45, 46], ulcerative colitis [44], Crohn’s disease [34], primary sclerosing cholangitis [42, 43, 44] and type I diabetes mellitus [39, 41]. The coincidental appearance of autoimmune pancreatitis with extrapancreatic autoimmune diseases strongly suggests a common pathogenesis. Various autoantibodies have been screened in patients with autoimmune pancreatitis and/or other autoimmune diseases. Among these are: antinuclear antibodies, antibacterial antibodies against lactoferrin, antiacinar anhydrase type II and pancreatic secretory trypsin inhibitor, etc. Okazaki et al. have reported detection rates of autoantibodies in 54 patients with autoimmune pancreatitis: anti-lactoferrin autoantibody: 75%, antinuclear: 65%, antiacinar anhydrase: 55%, antipancreatic secretory trypsin inhibitor: 33%, and rheumatoid factor: 25% [40]. Uchida et al. have demonstrated that mice developed pancreatitis as well as sialadenitis and cholangitis after subcutaneous injection with lactoferrin or carbonic anhydrase [47]. These findings described above suggest that an autoimmune mechanism may be involved in the pathogenesis of autoimmune pancreatitis, and lactoferrin is a candidate antigen as well as the other above-mentioned antigens. However, positivity for anti-lactoferrin autoantibody is not associated with a particular clinical or biochemical profile of the underlying disease and seems to reflect an immune reaction state. Overinterpretation is the major pitfall in the clinical application of the serological results.

**Anti-Lactoferrin Autoantibody in Serum**

Autoimmune pancreatitis is a relatively uncommon, non-alcoholic-related form of chronic pancreatitis...
Conclusion
In conclusion, lactoferrin may play various roles as a precipitate protein in pancreatic stone formation in chronic calcified pancreatitis and as an autoantigen in autoimmune pancreatitis. Further studies are required to better understand the role of lactoferrin.

Conflict of interest The authors have no potential conflicts of interest

References
19. Hekman A. Association of lactoferrin with other proteins, as demonstrated by changes in electrophoretic mobility. Biochim Biophys Acta 1971; 251:380-7. [PMID 11452880]
37. Kamisawa T, Okamoto A. Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease. J Gastroenterol 2006; 41:613-25. [PMID 16932997]


